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Abstract Searching for a peripheral biological marker for
schizophrenia, we previously reported on elevated mito-
chondrial complex I 75-kDa subunit mRNA-blood con-
centrations in early onset schizophrenia (EOS). The aim of
this study was to further evaluate the utility of this gene as
a potential marker for schizophrenia. Both—schizophrenia
and autism—are suggested to be neuronal maldevelopmen-
tal disorders with reports of mitochondrial dysfunction and
increased oxidative stress. Therefore we have investigated
the expression levels of mitochondrial complex I 75-kDa
subunit mRNA in whole blood of children with autistic
spectrum disorder (ASD) and a group of adolescent acute
first-episode EOS patients in comparison to matched con-
trols. We have found that compared to the respective
controls only the group of EOS patients—and not the ASD
group—showed a significantly altered expression of the
complex I 75-kDa subunit mRNA. Although further studies
are necessary to test for the specificity of this marker, our
findings point to the potential use of the mitochondrial
complex I as a biomarker for schizophrenia.
Keywords Biological marker  Mitochondrial complex I 
75-kDa subunit  Early onset schizophrenia 
Autistic spectrum disorder
Introduction
The severe psychiatric condition ‘‘schizophrenia’’ some-
times manifests in children and adolescents as early onset
schizophrenia (EOS). The clinical and biological hetero-
geneity of schizophrenia often hampers a rapid and defin-
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itive diagnosis. Since diagnostic procedures are only based
on descriptive behavioral information, a disease marker in
peripheral tissue would help to accelerate diagnosis and
monitor treatment course. In several studies [1–5]
researchers focused their analyses on the complex I of the
mitochondrial electron transporter system, due to the
repeatedly found abnormalities in cerebral energy metab-
olism and mitochondrial function in schizophrenia [6–18].
Ben-Shachar et al. described a high sensitivity and speci-
ficity for the mitochondrial complex I as a potential bio-
marker of schizophrenia. They found an increased
enzymatic activity of the complex I in schizophrenic
patients compared to controls [1]. Furthermore a positive
correlation between the enzymatic activity and psychotic
symptomatology was found [4].
In a recent study we showed increased levels of complex
I mRNA expression for the first time in a rare population of
adolescent EOS patients [19]. In schizophrenia research,
many studies pointed to a neurodevelopmental etiology of
this disorder [20, 21]. There is growing evidence that
abnormalities in prenatal or perinatal brain development
ultimately result in an increased predisposition to
schizophrenia.
Similarly to this disease concept, ASD is supposed to be
caused by a neuronal maldevelopment, reflected by cytoar-
chitectural abnormalities in many brain regions [22–24]. Just
like in schizophrenia pathophysiology, a variety of bio-
chemical, anatomical and neuroradiographic studies imply
an impairment of brain energy metabolism in ASD [25–30].
The aim of our study was to re-assess the relative utility
of mitochondrial complex I 75-kDa subunit mRNA levels
as a marker for schizophrenia. In order to assess whether
the increased 75-kDa subunit mRNA expression generally
reflects an abnormal neuronal development or whether it is
more closely related to schizophrenia, we have determined
the expression of this gene in a group of ASD children, and
in parallel in a group of acute first-episode EOS patients. In
both groups mRNA levels were assessed in whole blood
cells by real-time PCR in comparison to a respective age-
and gender-matched healthy control group. As a positive
control we have included the previously examined sample
group [19].
Methods
Subjects
Patients were recruited at the hospital for child and ado-
lescence psychiatry and psychotherapy of the University of
Wuerzburg and Ulm. The local ethics committees approved
this study and all subjects and parents gave their written
informed consent.
Typically developing healthy participants were recruited
from primary, secondary or grammar school. They were
screened for behavioral problems by the Achenbach Child
Behavior Check List (CBCL) [31]. Individuals were
excluded from the control group if they suffered from a
somatic or neurological disease, were taking medication or
exhibited abnormal CBCL scores.
We included into this study 10 patients with acute
first-episode, neuroleptic-naı¨ve EOS and 10 age- and
gender-matched controls of our previous report. These
samples were re-analyzed in parallel to the other two
groups as a positive control. For demographic details
please see [19].
Our second, independent schizophrenia sample con-
sisted of 12 patients (8 males, mean age 16.3 years, age
range from 13 years, 6 months to 17 years, 11 months; 4
females, mean age 16.6 years, age range from 15 years,
3 months to 17 years, 6 months) with acute first-episode
EOS (see Table 1). Schizophrenia diagnoses (see Table 1)
were determined by an experienced child psychiatrist
according to ICD-10/DSM-IV criteria. Blood was collected
in the acute, if possible neuroleptic-naı¨ve state. Four of the
12 schizophrenic patients were neuroleptic-naı¨ve, 8 had a
short period of drug treatment before the first blood with-
drawal (see Table 1). The brief psychiatric rating scale
(BPRS) [32] was performed concomitantly with the blood
withdrawal. This group was age-and gender-matched with
a group of 12 control children from our pool of controls
(for demographic details on age and CBCL scores see
Table 1).
The ASD group consisted of 16 male patients (mean age
13.6 years; age range from 8 years, 2 months to 18 years,
0 months). ASD diagnoses were based on the ICD-10/
DSM-IV criteria and determined by an experienced child
psychiatrist (see Table 2). Diagnoses were further con-
firmed by the following measures: The Questionnaire on
Behavioral and Social Communication (VSK) [33, 34], the
Autism Diagnostic Interview-Research [35, 36], and the
Autism Diagnostic Observation Schedule [37–39]. For the
ASD questionnaire mean scores and cut-offs see Table 2.
ASD patients with a known severe somatic or neurological
disorder as well as schizophrenia were excluded from the
study. For comorbid diagnoses and medication see Table 2.
The ASD group was age- and gender-matched with a group
of 16 healthy children (for demographic details on age and
CBCL scores see Table 2).
Isolation of total RNA
PAXgene blood RNA kit (PreAnalytiX, Hombrechtikon,
Switzerland) was used according to the manufacturers
instructions to isolate total RNA from blood followed by
DNAse treament (RNAse-free DNase Set, Quiagen, Oslo,
442 Eur Child Adolesc Psychiatry (2010) 19:441–448
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Norway). We evaluated the RNA purity and yield by
UV-spectroscopy.
Reverse transcription
For the reverse transcription we used the RETROscript kit
(Ambion, Cambridgeshire, UK) with the moloney murine
leukemia virus following the manufacturer’ s instructions
using oligo(dT) primers.
Real-time quantitative PCR
Primers were designed with Beacon Designer Software
(Biosoft International, Stratagene, La Jolla, CA, USA) and
synthesized commercially by Invitrogen (Custom Primers,
Karlsruhe, Germany). Real-time PCR was carried out at the
myIQ (Bio-Rad, Hercules, CA, USA) with AbsoluteTM
SYBR Green Fluorescein Mix (Abgene, Epsom, UK); each
sample in triplicate. Patient samples and matched controls
were run on the same plate in one experiment. We used
beta-actin as a housekeeping gene (in accordance with our
first protocoll, [19], for a better comparability). Primer
sequences, annealing temperature and product size of the
amplified product are shown in Table 3. PCR conditions
were the following: initial enzyme activation cycle 95C
(15 min), denaturation 94C (20 s), annealing TA (30 s),
elongation 72C (30 s), extra step at 80C to exclude pri-
mer dimers (15 s). 45 cycles of denaturation, annealing,
elongation and the extra step were used. For the optimi-
zation of the assay conditions and specificity we performed
melt curve analysis and gel electrophoresis. We also ana-
lyzed controls without reverse transcriptase and no tem-
plate controls. Our standard curves were performed in
triplicates and primer efficiency was determined to be
within a suitable range for the use of the 2^DDCT method.
Real time quantitative-PCR products were assessed in a 2%
agarose gel containing SYBR Save DNA gel stain (Invit-
rogen) with a 100 bp DNA ladder (Promega).
Data analysis and statistics
To compare gene expression levels we applied the
2^DDCT method using the Biorad iQ5 Optical System
Software version 2.0. When comparing age-and gender-
matched patient and control groups, two-tailed t-tests
were used, after normal distribution was confirmed by
Kolmogorov–Smirnov test. A two-tailed type I error rate of
5% was chosen.
For the analysis of the sensitivity and specificity of our
potential marker we calculated the 2^DDCT difference of
each matched patient-control-pair and determined the cut
off that separated best the EOS from the ASD group (by
receiver operating characteristic-curves in SPSS).
Results
All patients of our two independent schizophrenia groups
had a severe disease. Patients of our previously tested
sample [19], which we have included as positive control,
had a mean initial BPRS value (± standard deviation; SD)
of 58.1 ± 10.6. In our new, independent schizophrenia
group the mean initial BPRS value was 62.2 ± 16.4 (see
Table 1). The two groups did not differ in their mean
age ± SD, with 16.5 ± 3.3 years in the first and
16.4 ± 1.4 in the new sample. There were slightly more
female patients in the second group (20% in the first versus
33.3% in the new sample). The main diagnosis in both
Table 1 Demographic statistics of the second, independent EOS
sample and the matched control subjects
EOS patients
Age/gender
Male (n) 8
Age (years), mean ± SD 16.3 ± 1.7
Female (n) 4
Age (years), mean ± SD 16.6 ± 1.0
Schizophrenia ICD 10-diagnoses (n)
F20.0 paranoid schizophrenia 9
F20.2 catatonic schizophrenia 1
F25.0 schizoaffective disorder 2
Psychiatric co-medication (patients, n)
Drug-naı¨ve 4
On medication 8
Neuroleptics (olanzapine, quetiapine, clozapine,
chlorprothixen)
6
Tranquillizer (lorazepam) 3
Mood stabilizer (valproic acid) 1
Others 1
Initial BPRS (score ± SD) 62.2 ± 16.4
Control subjects
Age/gender
Male (n) 8
Age (years), mean ± SD 16.0 ± 1.0
Female (n) 4
Age (years), mean ± SD 16.6 ± 1.2
CBCL (score ± SD)
Male CBCL total 18.4 ± 11.5
Internalizing 5.4 ± 4.3
Externalizing 7.4 ± 5.3
Female CBCL total 7.7 ± 4.7
Internalizing 4.7 ± 4.6
Externalizing 1.3 ± 1.2
BPRS Brief Psychiatric Rating Scale, CBCL Child Behavior Check
List
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Table 3 Primer sequences, annealing temperatures and PCR product sizes
Name Gene bank code
(NCBI, Gene)
Primer sequences 50 to 30 Annealing
temperature
Product
size
75-kDa-
subunit = NDUFS1
BC030833 f-ATGTGCCTTGTTGAAATTGAGAAAG 62C 482
r-GCATAGGGCTTAGAGGTTAGGG
Beta-actin BC002409 f-TGAAGTGTGACGTGGACATCCG 62C 444
r-GCTGTCACCTTCACCGTTCCAG
NDUFS1 NADH dehydrogenase (ubiquinone) Fe–S protein 1
Table 2 Demographic statistics
of the 16 male ASD patients and
the matched control subjects
ADI-R Autism Diagnostic
Interview-Research, ADOS
Autism Diagnostic Observation
Schedule, ASD autistic spectrum
disorder, CBCL Child Behavior
Check List, FSK Fragebogen
zur Sozialen Kommunikation
[original version: Social
Communication Questionnaire
(SCQ)]
ASD patients (n 5 16, male)
Age (years), mean ± SD 13.6 ± 3.5
ASD ICD 10-diagnoses (n)
F84.0 Childhood autism 2
F84.1 Atypical autism 5
F84.5 Asperger’s syndrome 9
Comorbid ICD 10-diagnoses (n)
F31.3 Bipolar affective disorder, current episode mild or
moderate depression
1
F42.2 Mixed obsessional thoughts and acts 1
F80.0/ F81.1 Specific speech articulation disorder/expressive
language disorder
1/1
F83 Mixed specific developmental disorder 1
F90.0/90.1 Disturbance of activity and attention/hyperkinetic
conduct disorder
8/1
F93.3 Sibling rivalry disorder 1
F94.0 Elective mutism 1
F95.1/ F95.2 Chronic motor or vocal tic disorder/combined vocal
and multiple motor tic disorder
1/1
F98.0/ F98.1 Non-organic enuresis/encopresis 1/1
Psychiatric co-medication (patients, n)
Methylphenidate (including Medikinet ret., Concerta) 6
Amphetamine 2
Atomoxetine 1
Fluoxetine 2
Sertraline 1
Lithium acetate 1
Risperidone 1
Tiapridex 1
Autistic features (score ± SD)
FSK 19.9 ± 6.1
ADOS sum of communication and social interaction (autism
cut-off = 10, autistic spectrum disorder = 7)
11.5 ± 4.4
ADI-R social interaction (cut-off 10) 19.9 ± 8.4
ADI-R communication and language (cut-off for speaking children = 8) 15.0 ± 4.9
ADI-R repetitive behaviours and stereotyped pattern (cut-off = 3) 5.8 ± 3.1
ADI-R abnormal development before the age of 3 years (cut-off = 1) 2.5 ± 1.7
Control subjects (n 5 16, male)
Age (years), mean ± SD 14.2 ± 2.1
CBCL (score ± SD) CBCL total 13.8 ± 10.0
Internalizing 3.4 ± 3.5
Externalizing 5.6 ± 4.4
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samples was the ICD-10 F20.0, paranoid schizophrenia (80
versus 75%). One difference of the two groups was that in
our new, independent sample 4 of the 12 patients were
drug-naı¨ve and 8 were on a short period of neuroleptic
medication at the time of blood withdrawal.
The third group we have investigated included ASD
patients. In the ASD group, the requested cut-offs of the
state of the art standardized autism manuals were clearly
exceeded (all data see Table 2).
In our pool of controls we found a correlation between
age and 2^DDCT values with a higher 75-kDa/beta-actin
ratio in the younger persons (n = 24; r = -0.491,
P = 0.015). Therefore our respective control groups were
carefully age-matched. Comparing the twelve EOS ado-
lescents of our new, independent schizophrenia sample
with age- and gender-matched controls, revealed a signif-
icantly increased 75-kDa subunit mRNA expression (ratio
to beta-actin; 2^DDCT values: schizophrenia 1.6 ± 0.7
versus controls 0.9 ± 0.8; P = 0.027; for the 2^DDCT
values and means of pre-treated and drug-naı¨ve patients see
Fig. 1) similarly to the newly investigated positive control
group, where we could reproduce the increased 75-kDa
subunit mRNA expression in a different laboratory, by a
different investigator (ratio to beta-actin; 2^DDCT values:
schizophrenia 2.3 ± 2.1 versus controls 0.8 ± 0.4;
P = 0.053). The 2^DDCT values and mean of the two
combined EOS samples and two control samples are shown
in Fig. 2 (ratio to beta-actin; 2^DDCT values: schizo-
phrenia 1.9 ± 1.2 versus controls 0.9 ± 0.8; P = 0.003).
Comparing drug-naı¨ve with pre-treated EOS patients in the
second independent EOS sample [drug-naı¨ve (n = 4) ver-
sus pre-treated EOS (n = 8); P = 0.816; for a graphical
presentation of the respective 2^DDCT values see Fig. 1]
as well as in the combined EOS sample [drug-naı¨ve
(n = 14) versus pre-treated EOS (n = 8); P = 0.583] we
could not detect any 75-kDa gene expression differences.
Comparing the ASD group and age- and gender-mat-
ched controls, we could not detect any difference in mRNA
levels of the complex I 75-kDa subunit (ratio to beta-actin;
2^DDCT values: ASD 1.3 ± 0.9 versus controls
1.3 ± 1.2; P = 0.880; see Fig. 3), neither when comparing
the ASD patients on stimulant medication with the
untreated ones (P = 0.460; for a graphical presentation of
the respective 2^DDCT values see Fig. 3).
We found a sensitivity of the potential biomarker of 0.82
and a specificity of 0.63.
Discussion
The aim of our study was to further evaluate the utility of
mitochondrial complex I 75-kDa subunit mRNA levels as a
Fig. 1 Mitochondrial complex I 75-kDa subunit gene expression in
the second, independent early onset schizophrenia patients sample
(pre-treated and drug-naı¨ve) and the matched control subjects
Fig. 2 Mitochondrial complex I 75-kDa subunit gene expression in
the two combined EOS patients samples (pre-treated and drug-naı¨ve)
and the combined control groups
Fig. 3 Mitochondrial complex I 75-kDa subunit gene expression in
the ASD patients sample (patients with and without stimulants) and
the matched control subjects
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potential biomarker for schizophrenia. In order to assess
whether the increased 75-kDa expression generally reflects
an abnormal neuronal development or whether it is more
closely associated with schizophrenia we have determined
the expression of this gene in a group of ASD children, and
in parallel in a group of acute first-episode EOS patients. In
both groups mRNA levels were assessed in whole blood
cells by real-time PCR in comparison to a respective age-
and gender-matched healthy control group. As a positive
control we have included the previously examined sample
group [19]. As all EOS and ASD patients showed a strong
symptomatology—assessed by the state of the art manu-
als—suggest the comparison of the 75-kDa gene expres-
sion in these two neuronal maldevelopmental disorders for
evaluating the utility of this gene as a potential marker for
schizophrenia.
In our study we observed an increased 75-kDa subunit
expression in our two independent samples of EOS. In the
ASD group we were not able to detect any altered gene
expression. Our potential marker separated our EOS and
ASD groups with a sensitivity of 0.82 and specificity of
0.63. For a final evaluation of specificity further studies on
patients with other psychiatric disorders are certainly nee-
ded. To increase sensitivity and specificity, probably a set
of different biomarkers (such as different gene variants,
markers on the level of mRNA and protein expression in
combination with functional imaging data etc.) should be
used. Such specific biomarkers would allow an early
diagnosis and treatment monitoring of schizophrenia.
There are several reports, that peripheral gene expres-
sion/activity is correlated with gene expression/metabolic
function in the central nervous system (CNS). Sullivan
et al. [40] performed a study on the comparability of gene
expression in blood and brain. It was found that about half
of a set of candidate genes relevant to schizophrenia were
expressed in both whole blood and prefrontal cortex tissue.
Furthermore it was found, that the complex I activity in
platelet mitochondria was positively correlated with the
cerebral glucose metabolism in basal ganglia and thalamus,
two brain regions implicated in schizophrenia [2]. Findings
such as these affirm that it is reasonable and useful to
search for disease markers in peripheral tissue as surrogate
for central processes, as in our study.
Although this study might be limited by the small
sample size, our results are in line with former reports of an
increased gene expression and activity of mitochondrial
complex I in schizophrenia. Mitochondrial complex I
locates at the mitochondrial inner membrane and is com-
posed of 45 different subunits. Our candidate gene, the
75-kDa subunit, is the largest iron–sulfur non-catalytic
transmembrane protein of the complex I [1, 4]. It has NADH
dehydrogenase and oxidoreductase activity and transfers
electrons from NADH to the respiratory chain. Functional
abnormalities in this subunit might impact on the electron
transport of NADH to oxygen and finally on the cellular
ATP production, leading to various brain dysfunctions,
such as seen in schizophrenia pathophysiology. Ben-
Shachar et al. described a high sensitivity and specificity
for potential mitochondrial complex I markers in adults
with schizophrenia [1, 4]. They found an increased enzy-
matic activity of the complex I in schizophrenic patients
compared to controls and patients with affective disorders
[1]. Dror et al. [4] observed concordantly, that increased
mitochondrial complex I activity was associated with
psychotic symptomology, while its decrease was observed
in patients with residual schizophrenia. There are also
several reports of brain region-dependent altered gene
expression of mitochondrial complex I subunits in post-
mortem tissue of schizophrenic patients. Association
studies additionally pointed to a modulating effect of
complex I gene variants in schizophrenic psychosis [41].
As a possible confounding factor of our results, gene
expression of the 75-kDa subunit might be influenced by
medication. Most of our ASD patients were on medication,
mainly on stimulant drugs. There is little data published on
methylphenidate effects on the respiratory chain. In one
report chronic methylphenidate administration increased
the CNS expression of mitochondrial complex II and IV
genes in a tissue dependent way [42]. Under chronic
amphetamine abuse, an increased oxidative stress was
repeatedly found (e.g., [43]), suggesting altered mito-
chondrial function. Half of our second, independent EOS
sample were under a short duration antipsychotic medica-
tion at time of blood withdrawal (see Table 1). Under
chronic antipsychotic treatment, Casademont et al. [44]
monitored a reduction of mitochondrial complex I activity
in peripheral blood mononuclear cells in comparison to the
drug-naı¨ve status. There was also a decrease of complex I
activity seen when antipsychotics were added, in vitro, to
mitochondria isolated from human and rat brains [1, 45,
46]. However, the observation of tissue-specific effects of
neuroleptics on complex I activity in vivo (activity
reduction in rat brain, but not in muscle) might explain the
varying results [47, 48]. Several reports disproved a pos-
sible confounding influence of antipsychotics on complex I
expression. Whatley et al. [49, 50] reported that neuro-
leptics did not modify the complex I NADH-coenzyme Q
reductase nor rotenone-resistant NADH cytochrome C
reductase activity in postmortem frontal cortex of schizo-
phrenic patients. Ben-Shachar et al. [1] found a similar
complex I activity in unmedicated and medicated patients.
Also our previous results confirmed these observations, as
the increased 75-kDa expression was seen in the neuro-
leptic-naı¨ve patients as well as after a three month anti-
psychotic treatment [19]. In our current study we observed
the increased 75-kDa subunit gene expression in our new,
446 Eur Child Adolesc Psychiatry (2010) 19:441–448
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independent EOS sample in the drug-naı¨ve state as well as
under a short antipsychotic treatment. Observing elevated
75-kDa subunit mRNA levels in the medicated and
unmedicated acutely and chronically psychotic state, but
not in residual schizophrenia [1, 4, 19] suggests the mito-
chondrial 75-kDa-subunit as a potential state marker of
schizophrenia.
Conclusion
In conclusion, our results strengthen the role of the mito-
chondrial complex I as a potential peripheral biomarker for
schizophrenia. The observed increase in 75-kDa subunit
mRNA expression is in line with other reports on altered
complex I activity in schizophrenic psychosis and further
findings of increased oxidative stress in schizophrenia
pathophysiology [18, 51]. Although further studies are
needed to confirm the specificity it might become a con-
venient supporting peripheral marker for an early clinical
diagnosis and treatment of this disease.
References
1. Ben-Shachar D, Zuk R, Gazawi H, Reshef A, Sheinkman A,
Klein E (1999) Increased mitochondrial complex I activity in
platelets of schizophrenic patients. Int J Neuropsychopharmacol
2:245–253
2. Ben-Shachar D, Bonne O, Chisin R, Klein E, Lester H, Aharon-
Peretz J, Yona I, Freedman N (2007) Cerebral glucose utilization
and platelet mitochondrial complex I activity in schizophrenia: a
FDG-PET study. Prog Neuropsychopharmacol Biol Psychiatry
31:807–813
3. Ben-Shachar D, Karry R (2007) Sp1 expression is disrupted in
schizophrenia; a possible mechanism for the abnormal expression
of mitochondrial complex I genes, NDUFV1 and NDUFV2.
PLoS One 2:e817
4. Dror N, Klein E, Karry R, Sheinkman A, Kirsh Z, Mazor M
(2002) State-dependent alterations in mitochondrial complex I
activity in platelets: a potential peripheral marker for schizo-
phrenia. Mol Psychiatry 7:995–1001
5. Karry R, Klein E, Ben-Shachar D (2004) Mitochondrial complex
I subunits expression is altered in schizophrenia: a postmortem
study. Biol Psychiatry 55:676–684
6. Ben-Shachar D (2002) Mitochondrial dysfunction in schizo-
phrenia: a possible linkage to dopamine. J Neurochem 83:1241–
1251
7. Ben-Shachar D, Laifenfeld D (2004) Mitochondria, synaptic
plasticity, and schizophrenia. Int Rev Neurobiol 59:273–296
8. Buchsbaum MS (1990) The frontal lobes, basal ganglia, and tem-
poral lobes as sites for schizophrenia. Schizophr Bull 16:379–389
9. Buchsbaum MS, Nuechterlein KH, Haier RJ, Wu J, Sicotte N,
Hazlett E, Asarnow R, Potkin S, Guich S (1990) Glucose meta-
bolic rate in normals and schizophrenics during the continuous
performance test assessed by positron emission tomography.
Br J Psychiatry 156:216–227
10. Buchsbaum MS, Buchsbaum BR, Hazlett EA, Haznedar MM,
Newmark R, Tang CY, Hof PR (2007) Relative glucose
metabolic rate higher in white matter in patients with schizo-
phrenia. Am J Psychiatry 164:1072–1081
11. Cohen RM, Semple WE, Gross M, Nordahl TE, King AC, Pickar
D, Post RM (1989) Evidence for common alterations in cerebral
glucose metabolism in major affective disorders and schizo-
phrenia. Neuropsychopharmacology 2:241–254
12. Gur RE, Mozley PD, Resnick SM, Mozley LH, Shtasel DL,
Gallacher F, Arnold SE, Karp JS, Alavi A, Reivich M et al (1995)
Resting cerebral glucose metabolism in first-episode and previ-
ously treated patients with schizophrenia relates to clinical
features. Arch Gen Psychiatry 52:657–667
13. Hazlett EA, Buchsbaum MS, Haznedar MM, Singer MB, Ger-
mans MK, Schnur DB, Jimenez EA, Buchsbaum BR, Troyer BT
(1998) Prefrontal cortex glucose metabolism and startle eyeblink
modification abnormalities in unmedicated schizophrenia
patients. Psychophysiology 35:186–198
14. Hazlett EA, Buchsbaum MS, Kemether E, Bloom R, Platholi J,
Brickman AM, Shihabuddin L, Tang C, Byne W (2004) Abnor-
mal glucose metabolism in the mediodorsal nucleus of the thal-
amus in schizophrenia. Am J Psychiatry 161:305–314
15. Haznedar MM, Buchsbaum MS, Hazlett EA, Shihabuddin L,
New A, Siever LJ (2004) Cingulate gyrus volume and metabo-
lism in the schizophrenia spectrum. Schizophr Res 71:249–262
16. Iwamoto K, Bundo M, Kato T (2005) Altered expression of
mitochondria-related genes in postmortem brains of patients with
bipolar disorder or schizophrenia, as revealed by large-scale
DNA microarray analysis. Hum Mol Genet 14:241–253
17. Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P (2002)
Gene expression profiling reveals alterations of specific metabolic
pathways in schizophrenia. J Neurosci 22:2718–2729
18. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT,
Griffin JL, Wayland M, Freeman T, Dudbridge F, Lilley KS,
Karp NA et al (2004) Mitochondrial dysfunction in schizophre-
nia: evidence for compromised brain metabolism and oxidative
stress. Mol Psychiatry 9:684–697 643
19. Mehler-Wex C, Duvigneau JC, Hartl RT, Ben-Shachar D,
Warnke A, Gerlach M (2006) Increased mRNA levels of the
mitochondrial complex I 75-kDa subunit. A potential peripheral
marker of early onset schizophrenia? Eur Child Adolesc
Psychiatry 15:504–507
20. Durany N, Thome J (2004) Neurotrophic factors and the patho-
physiology of schizophrenic psychoses. Eur Psychiatry 19:326–337
21. Rapoport JL, Addington AM, Frangou S, Psych MR (2005) The
neurodevelopmental model of schizophrenia: update. Mol Psy-
chiatry 10:434–449
22. Geschwind DH, Levitt P (2007) Autism spectrum disorders:
developmental disconnection syndromes. Curr Opin Neurobiol
17:103–111
23. Palmen SJ, van Engeland H, Hof PR, Schmitz C (2004) Neuro-
pathological findings in autism. Brain 127:2572–2583
24. Polleux F, Lauder JM (2004) Toward a developmental neurobi-
ology of autism. Ment Retard Dev Disabil Res Rev 10:303–317
25. Chauhan A, Chauhan V, Brown WT, Cohen I (2004) Oxidative
stress in autism: increased lipid peroxidation and reduced serum
levels of ceruloplasmin and transferrin—the antioxidant proteins.
Life Sci 75:2539–2549
26. Filipek PA, Juranek J, Smith M, Mays LZ, Ramos ER, Bocian M,
Masser-Frye D, Laulhere TM, Modahl C, Spence MA, Gargus JJ
(2003) Mitochondrial dysfunction in autistic patients with 15q
inverted duplication. Ann Neurol 53:801–804
27. Fillano JJ, Goldenthal MJ, Rhodes CH, Marı´n-Garcı´a J (2002)
Mitochondrial dysfunction in patients with hypotonia, epilepsy,
autism, and developmental delay: HEADD syndrome. J Child
Neurol 17:435–439
28. Graf WD, Marin-Garcia J, Gao HG, Pizzo S, Naviaux RK,
Markusic D, Barshop BA, Courchesne E, Haas RH (2000)
Eur Child Adolesc Psychiatry (2010) 19:441–448 447
123
Autism associated with the mitochondrial DNA G8363A transfer
RNA(Lys) mutation. J Child Neurol 15:357–361
29. Pons R, Andreu AL, Checcarelli N, Vila` MR, Engelstad K, Sue
CM, Shungu D, Haggerty R, de Vivo DC, DiMauro S (2004)
Mitochondrial DNA abnormalities and autistic spectrum disor-
ders. J Pediatr 144:81–85
30. So¨gu¨t S, Zoroglu SS, Ozyurt H, Yilmaz HR, Ozugurlu F, Sivasli
E, Yetkin O, Yanik M, Tutkun H, Savas HA, Tarakc¸ioglu M,
Akyol O (2003) Changes in nitric oxide levels and antioxidant
enzyme activities may have a role in the pathophysiological
mechanisms involved in autism. Clin Chim Acta 331:111–117
31. Achenbach TM, Edelbrock CS (1981) Behavioural problems and
competencies reported by parents of normal and disturbed
children aged four through sixteen. Monogr Soc Res Child Dev
46:1–82
32. Overall JE, Gorham DR (1962) The brief psychiatric rating scale.
Psychol Rep 10:799–812
33. Rutter M, Bailey A, Berument SK, Le Couteur A, Lord C, Pickles
A (2003) Social communication questionnaire (SCQ). Western
Psychological Services, Los Angeles
34. Bolte S, Poustka F (2006) FSK—Fragebogen zur Sozialen
Kommunikation. Huber, Bern
35. Lord C, Rutter M, Le Couteur A (1994) Autism diagnostic
interview-revised: a revised version of a diagnostic interview for
caregivers of individuals with possible pervasive developmental
disorders. J Autism Dev Disord 24:659–685
36. Bolte S, Ru¨hl D, Schmo¨tzer G, Poustka F (2006) ADI-R. Diag-
nostisches Interview fu¨r Autismus —Revidiert. Huber, Bern
37. Lord C, Rutter M, Goode S, Hemsbergen J, Jordan H, Mawhood
L, Schopler E (1989) Autism Diagnostic Observation Schedule:
a standardized observation of communicative and social behav-
ior. J Autism Dev Disord 19:185–212
38. Lord C, Risi S, Lambrecht L, Cook EH Jr, Leventhal BL, DiL-
avore PC, Pickles A, Rutter M (2000) The autism diagnostic
observation schedule-generic: a standard measure of social and
communication deficits associated with the spectrum of autism.
J Autism Dev Disord 30:205–223
39. Ruehl D, Bolte S, Feineis-Matthews S, Poustka F (2004)
ADOS—Diagnostische Beobachtungsskala fuer Autistische Sto-
erungen. Huber, Bern
40. Sullivan PF, Fan C, Perou CM (2006) Evaluating the compara-
bility of gene expression in blood and brain. Am J Med Genet B
Neuropsychiatr Genet 141B:261–268
41. Washizuka S, Kametani M, Sasaki T, Tochigi M, Umekage T,
Kohda K, Kato T (2006) Association of mitochondrial complex I
subunit gene NDUFV2 at 18p11 with schizophrenia in the Jap-
anese population. Am J Med Genet B Neuropsychiatr Genet
141B:301–304
42. Fagundes AO, Rezin GT, Zanette F, Grandi E, Assis LC, Dal-
Pizzol F, Quevedo J, Streck EL (2007) Chronic administration of
methylphenidate activates mitochondrial respiratory chain in
brain of young rats. Int J Dev Neurosci 25:47–51
43. Frey BN, Valvassori SS, Gomes KM, Martins MR, Dal-Pizzol F,
Kapczinski F, Quevedo J (2006) Increased oxidative stress in
submitochondrial particles after chronic amphetamine exposure.
Brain Res 1097(1):224–229
44. Casademont J, Garrabou G, Miro´ O, Lo´pez S, Pons A, Bernardo
M, Cardellach F (2007) Neuroleptic treatment effect on mito-
chondrial electron transport chain: peripheral blood mononuclear
cells analysis in psychotic patients. Clin Psychopharmacol
27:284–288
45. Burkhardt C, Kelly JP, Lim YH, Filley CM, Parker WD (1993)
Neuroleptic medications inhibit complex I of the electron trans-
port chain. Ann Neurol 33:512–517
46. Maurer I, Moller HJ (1997) Inhibition of complex I by neuro-
leptics in normal human brain cortex paralles the extrapyramidal
toxicity of neuroleptics. Mol Cell Biochem 174:255–259
47. Barrientos A, Marin C, Miro O, Casademont J, Gomez M, Nunes
V, Tolosa E, Urbano-Marquez A, Cardellach F (1998) Bio-
chemical and molecular effects of chronic haloperidol adminis-
tration on brain and muscle mitochondria of rats. J Neurosci Res
53:475–481
48. Prince JA, Yassin MS, Oreland L (1997) Neuroleptic-induced
mitochondrial enzyme alterations in the rat brain. J Pharmacol
Exp Ther 280:261–267
49. Whatley SA, Curi D, Marchbanks RM (1996) Mitochondrial
involvement in schizophrenia and other functional psychoses.
Neurochem Res 21:995–1004
50. Whatley SA, Curi D, Das Gupta F, Ferrier IN, Jones S, Taylor C,
Marchbanks RM (1998) Superoxide, neuroleptics and the ubi-
quinone and cytochrome b5 reductases in brain and lymphocytes
from normals and schizophrenic patients. Mol Psychiatry 3:227–
237
51. Yao JK, Reddy RD, van Kammen DP (2001) Oxidative damage
and schizophrenia. An overview of the evidence and its thera-
peutic implications. CNS Drugs 15:287–310
448 Eur Child Adolesc Psychiatry (2010) 19:441–448
123
